KTTA
NASDAQ · Biotechnology
Pasithea Therapeutics Corp
$0.48
-0.02 (-3.85%)
Open$0.49
Previous Close$0.50
Day High$0.50
Day Low$0.45
52W High$2.06
52W Low$0.28
Volume—
Avg Volume181.2K
Market Cap16.68M
P/E Ratio—
EPS$-1.48
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,508.3% upside
Current
$0.48
$0.48
Target
$26.92
$26.92
$19.73
$26.92 avg
$29.00
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 426.2K | 3.90M | 3.72M |
| Net Income | -423,372,815 | 467.4K | 601.6K |
| Profit Margin | -14,394.0% | 12.0% | 16.2% |
| EBITDA | -423,356,547 | 1.16M | 1.10M |
| Free Cash Flow | — | 801.3K | 617.9K |
| Rev Growth | — | +18.2% | +4.0% |
| Debt/Equity | — | 0.89 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |